Cannabigerol (CBG) is a cannabinoid found in the cannabis plant. Often referred to as the “mother cannabinoid,” CBG is the precursor to better-known compounds like cannabidiol (CBD) and tetrahydrocannabinol (THC). As the plant matures, CBG is naturally converted into these other cannabinoids, which is why only small amounts remain in most cannabis strains.
Although CBG is present in smaller quantities, early studies suggest it interacts with CB1 and CB2 receptors, as well as other receptors in the body. It’s being explored for potential anti-inflammatory, antibacterial, and neuromodulatory properties, however, research is still in the early stages, and its medical applications are not yet fully understood.
CBG is considered a promising compound within medical cannabis research. It does not produce intoxication and is being studied for its possible role in supporting conditions that require multi-targeted approaches.
Whilst CBG and CBD share some important targets, such as the CB1 and CB2 receptors, they act on an array of different receptors to cause different effects. Therefore it is not a case of CBG or CBD being stronger than one another, rather assessing their ability to cause a certain effect.
CBG may be legal when contained within a legally prescribed medical cannabis product. In addition to this, CBG itself is not a controlled substance so cannabis-derived products containing CBG are legal in the UK so long as the product does not contain higher than permitted amounts of controlled cannabinoids such as THC and cannabinol (CBN).
Direct: [email protected]
PR Agency: [email protected]
Head Office Address: Curaleaf Clinic, 10 Harley St, London W1G 9QY
Postal Address: Curaleaf Clinic, PO Box 1436, Sunderland, SR5 9UE
| Overall Rating for this Location | Good |
| Are Services Well-led? | Outstanding |
